drugset / Trial / NCT07560111
A Phase II Study of GC101 in NSCLC
NaSingle-groupOpen-labelTreatment
Summary
28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Tumor Infiltrating Lymphocytes | Cell therapy | — | — |